"For more than 120 years, Methodist Hospital has cared for Nebraska's families. Dedicated to superior service and a deep understanding of patient care, Omaha's Methodist Hospital sets the standards for health care to ensure you always have the care you need - when you need it."

During the past decade, Nebraska Methodist Hospital conducted 177 clinical trials. In the 10-year time frame, 177 clinical trials started and 159 clinical trials were completed, i.e. on average, 89.8% percent of trials that started reached the finish line to date. In the past 5 years, 69 clinical trials started and 89 clinical trials were completed. i.e. 129% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Nebraska Methodist Hospital" #1 sponsor was "National Cancer Institute (NCI)" with 122 trials, followed by "Alliance for Clinical Trials in Oncology" with 20 trials sponsored, "SWOG Cancer Research Network" with 20 trials sponsored, "Gynecologic Oncology Group" with 18 trials sponsored and "NRG Oncology" with 18 trials sponsored. Other sponsors include 124 different institutions and companies that sponsored additional 70 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Nebraska Methodist Hospital" #1 collaborator was "National Cancer Institute (NCI)" with 101 trials as a collaborator, "NRG Oncology" with 60 trials as a collaborator, "Canadian Cancer Trials Group" with 8 trials as a collaborator, "Cancer and Leukemia Group B" with 5 trials as a collaborator and "Genentech, Inc." with 5 trials as a collaborator. Other collaborators include 101 different institutions and companies that were collaborators in the rest 74 trials.

According to Clinical.Site data, the most researched conditions in "Nebraska Methodist Hospital" are "Recurrent Ovarian Carcinoma" (22 trials), "Recurrent Fallopian Tube Carcinoma" (16 trials), "Recurrent Primary Peritoneal Carcinoma" (15 trials), "Endometrial Serous Adenocarcinoma" (13 trials) and "Endometrial Clear Cell Adenocarcinoma" (11 trials). Many other conditions were trialed in "Nebraska Methodist Hospital" in a lesser frequency.

Most popular intervention types in "Nebraska Methodist Hospital" are "Drug" (265 trials), "Other" (157 trials), "Biological" (99 trials), "Procedure" (58 trials) and "Radiation" (51 trials). Other intervention types were less common.

The name of intervention was led by "Laboratory Biomarker Analysis" (91 trials), "Quality-of-Life Assessment" (68 trials), "Paclitaxel" (47 trials), "Carboplatin" (44 trials) and "Questionnaire Administration" (36 trials). Other intervention names were less common.

The vast majority of trials in "Nebraska Methodist Hospital" are 220 trials for "All" genders, 90 trials for "Female" genders and 14 trials for "Male" genders.

Currently, there are NaN active trials in "Nebraska Methodist Hospital". undefined are not yet recruiting, 57 are recruiting, 118 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 110 completed trials in Nebraska Methodist Hospital, 5 suspended trials, and 27 terminated clinical trials to date.

Out of the total trials that were conducted in Nebraska Methodist Hospital, 23 "Phase 1" clinical trials were conducted, 162 "Phase 2" clinical trials and 151 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 3 trials, and there were also 12 trials that are defined as “Not Applicable".

Nebraska Methodist Hospital has several departments that took part in Clinical trials: "Methodist Estabrook Cancer Center" - 198 trials, "Methodist Physicians Clinic-Heart Consultants" - 13 trials, "Diabetes and Endocrine Associates" - 6 trials, "Colon and Rectal Surgery, Inc" - 4 trials